Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $58.00

Maze Therapeutics (NASDAQ:MAZE) had its target price increased by Guggenheim from $46.00 to $58.00 in a research note published on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also commented on MAZE. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Wells Fargo & Company assumed coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. Raymond James Financial assumed coverage on shares of Maze Therapeutics in a report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price for the company. Finally, Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Maze Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $48.57.

Maze Therapeutics Stock Down 1.0%

MAZE stock opened at $44.83 on Wednesday. The firm has a market capitalization of $2.16 billion, a PE ratio of -2.14 and a beta of 4.47. Maze Therapeutics has a twelve month low of $6.71 and a twelve month high of $49.25. The stock’s 50 day moving average is $43.91 and its 200-day moving average is $34.33.

Insider Buying and Selling

In related news, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Thursday, January 29th. The stock was sold at an average price of $44.27, for a total transaction of $332,025.00. Following the sale, the insider directly owned 10,503 shares in the company, valued at approximately $464,967.81. This trade represents a 41.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Amy Bachrodt sold 5,000 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total value of $230,200.00. Following the completion of the transaction, the senior vice president directly owned 12,965 shares in the company, valued at approximately $596,908.60. This represents a 27.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 200,000 shares of company stock worth $8,254,792.

Hedge Funds Weigh In On Maze Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. increased its holdings in Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock worth $56,040,000 after buying an additional 438,274 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock valued at $130,197,000 after acquiring an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Maze Therapeutics by 27.1% during the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock valued at $70,307,000 after acquiring an additional 362,060 shares during the period. Woodline Partners LP increased its stake in shares of Maze Therapeutics by 10.0% during the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after purchasing an additional 94,529 shares during the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Maze Therapeutics by 9.0% during the 4th quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock worth $35,111,000 after purchasing an additional 69,771 shares during the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.